New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 31, 2013
05:44 EDTCTICCTI announces DSMB recommendation to continue GOG-0212 Phase 3 trial of Opaxio
Cell Therapeutics, or CTI, announced that the Gynecologic Oncology Group, or GOG, informed CTI that an independent Data Safety Monitoring Board, or DSMB, recommended continuation of the GOG-0212 Phase 3 clinical trial of Opaxio as maintenance therapy in ovarian cancer with no changes following a planned interim survival analysis. CTI remains blinded to the interim analysis results. GOG-0212 is the largest maintenance study in this setting, having enrolled approximately 1,000 of the planned 1,100 patients. Enrollment is expected to be completed in 2013. The trial is being conducted and managed by the GOG, which is one of the National Cancer Institute's funded cooperative cancer research groups focused on the study of gynecologic malignancies.
News For CTIC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 21, 2014
16:54 EDTCTICCTI BioPharma files to sell 9M shares of common stock for holders
16:40 EDTCTICCTI BioPharma files $200M mixed securities shelf
Subscribe for More Information
November 19, 2014
07:09 EDTCTICJefferies to hold a conference
2014 Global London Healthcare Conference is being held in London, England on November 19-20.
November 17, 2014
11:06 EDTCTICLeerink biotech analysts hold an analyst/industry conference call
Subscribe for More Information
November 13, 2014
13:32 EDTCTICLeerink biotech analysts hold an analyst/industry conference call
Subscribe for More Information
13:29 EDTCTICLeerink biotech analysts hold an analyst/industry conference call
Subscribe for More Information
13:26 EDTCTICLeerink biotech analysts hold an analyst/industry conference call
Biotech Analysts provide a preview of items being discussed at the upcoming 56th Annual Meeting of ASH including Leukemia/MDS on an Analyst/Industry conference call to be held on November 20 at 10 am.
November 11, 2014
16:14 EDTCTICLeerink biotech analysts hold an analyst/industry conference call
Biotech Analysts provide a preview of items being discussed at the upcoming 56th Annual Meeting of ASH including JAK inhibitors, novel Jakafi combinations for Myelofibrosis and developing compounds on an Analyst/Industry conference call to be held on November 17 at 10 am.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use